

# Registry of procalcitonin-guided antibiotic therapy in patients with lower respiratory tract infections outside of study conditions: ProREAL - a real-life" survey

<b>Submission date</b> 18/09/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 16/10/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 17/07/2012	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Werner Albrich

**Contact details**  
Tellstrasse  
Kantonsspital Aarau  
Aarau  
Switzerland  
5001

## Additional identifiers

## Study information

**Scientific Title**

**Acronym**  
ProREAL

## **Study objectives**

Duration of antibiotic therapy for patients with lower respiratory tract infections can be shortened by application of a procalcitonin-based algorithm in real-life conditions.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Switzerland:

1. Ethics Committee of Aargau (Kantonale Ethikkommission Kanton Aargau) (EKAG), approved on 06/10/2008 (ref: 2006/48)
2. Ethics Committee of Basel (Ethikkommission Beider Basel) (EKBB), approved on 29/07/2008 (ref: 236/08)

Ethics approvals for trial centres in France: Pending as of 18/09/2009

## **Study design**

Observational prospective longitudinal study

## **Primary study design**

Observational

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Respiratory tract infections

## **Interventions**

The participants will be contacted approximately 30 days after the start of the treatment to conduct a telephone interview lasting approximately 10 minutes. They will be asked about any persisting complaints, possible side-effects of the antibiotics (such as diarrhoea and nausea) and recurrence of the respiratory tract infection with or without antibiotic treatment. They will also be asked whether they had to visit the GP or the hospital, and if so, how many times.

## **Intervention Type**

Other

## **Phase**

Not Applicable

## **Primary outcome(s)**

Duration of antibiotic treatment

All primary and secondary outcome measures will be assessed by a telephone interview 30 days after the start of the treatment.

## **Key secondary outcome(s)**

1. Adherence to procalcitonin algorithm
2. Adverse medical outcomes (complications, mortality, relapse, intensive care unit [ICU])

admission)

3. Antibiotic side effects

4. Length of hospital stay

5. Differences between procalcitonin (PCT) levels measured by KRYPTOR® and VIDAS®

All primary and secondary outcome measures will be assessed by a telephone interview 30 days after the start of the treatment.

**Completion date**

09/09/2011

## Eligibility

**Key inclusion criteria**

1. Both males and females, age >18

2. Lower respiratory tract infection (at least one respiratory symptom [cough, sputum production, dyspnea, tachypnea, pleuritic pain]) PLUS

3. One of the following auscultatory finding or sign of infection:

3.1. Core body temperature >38°C or <36°C

3.2. Shivers

3.3. Leukocyte count >10 g/L or <4 g/L cells

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

Does not meet inclusion criteria

**Date of first enrolment**

10/09/2009

**Date of final enrolment**

09/09/2011

## Locations

**Countries of recruitment**

France

Switzerland

### **Study participating centre**

Tellstrasse

Aarau

Switzerland

5001

## **Sponsor information**

### **Organisation**

BioMérieux (France)

### **ROR**

<https://ror.org/03hf69k85>

## **Funder(s)**

### **Funder type**

Hospital/treatment centre

### **Funder Name**

Aarau Hospital (Switzerland)

### **Funder Name**

BioMerieux (France) provides the procalcitonin test kits

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration

### **Study outputs**

Output type

Details  
results

Date created Date added Peer reviewed? Patient-facing?

<a href="#">Results article</a>		14/05/2012		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes